Patents for A61P 35 - Antineoplastic agents (221,099)
03/2002
03/28/2002WO2002024706A2 Water soluble rapamycin esters
03/28/2002WO2002024705A1 Stereoselective process for preparing cyclohexyl amine derivatives
03/28/2002WO2002024702A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
03/28/2002WO2002024698A1 Xanthine phosphodiesterase v inhibitors
03/28/2002WO2002024694A1 Pyrazolopyridines and pyrazolopyridazines as antidiabetics
03/28/2002WO2002024693A1 A process for producing 3,4-dihydro naphthyridinone analogs
03/28/2002WO2002024692A1 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
03/28/2002WO2002024687A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
03/28/2002WO2002024686A2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
03/28/2002WO2002024683A1 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
03/28/2002WO2002024682A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
03/28/2002WO2002024681A2 Pyrazine derivatives as modulators of tyrosine kinases
03/28/2002WO2002024680A1 Imidazole derivatives as raf kinase inhibitors
03/28/2002WO2002024679A1 PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY
03/28/2002WO2002024674A1 Benzoic acid derivatives and uses thereof
03/28/2002WO2002024665A1 Arylalkane-sulfonamides having endothelin-antagonist activity
03/28/2002WO2002024653A1 Compounds and methods for modulation of estrogen receptors
03/28/2002WO2002024651A1 A process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs
03/28/2002WO2002024639A1 Cyclopentane derivatives as therapeutic agents
03/28/2002WO2002024636A2 N-acylsulfonamide apoptosis promoters
03/28/2002WO2002024610A2 Method for producing an antineoplastic
03/28/2002WO2002024235A2 Prochelators of radiometal labeled molecules
03/28/2002WO2002024227A1 Tumor cell proliferation inhibitors
03/28/2002WO2002024226A2 Photosensitisers
03/28/2002WO2002024224A2 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
03/28/2002WO2002024222A2 Ligands for g protein coupled receptors and methods of using them
03/28/2002WO2002024221A2 Notch receptor agonists and uses
03/28/2002WO2002024219A1 Growth factor complex
03/28/2002WO2002024216A2 Method for use of igf-binding protein for selective sensitization of target cells in vivo
03/28/2002WO2002024214A2 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders
03/28/2002WO2002024210A2 Halogen compounds for use in medicine
03/28/2002WO2002024187A2 Treatment of diseases with adamantane derivatives
03/28/2002WO2002024179A2 Method for reducing toxicity of combined chemotherapies
03/28/2002WO2002024178A2 Method for reducing toxicity of combined chemotherapies
03/28/2002WO2002024146A2 Methods of decreasing or preventing pain using spicamycin derivatives
03/28/2002WO2002023994A1 A method for limiting the growth of cancer cells using an attenuated measles virus
03/28/2002WO2002011743A3 Treatment of prostate cancer
03/28/2002WO2002004624A9 Novel g protein-coupled receptor protein and dna thereof
03/28/2002WO2002002595A9 Amphipathic linear peptides and compositions containing same
03/28/2002WO2001096336A3 6,5-fused bicyclic heterocycles
03/28/2002WO2001090153A8 Reagents for cell selection and methods of use
03/28/2002WO2001085762B1 Cancer diagnosis and assays for screening anti-cancer agents
03/28/2002WO2001079249A3 Peptide nucleic acid derivatives with a negative charge, agents and methods for producing them
03/28/2002WO2001077150A3 Serine-threonine kinase
03/28/2002WO2001076575A3 The treatment of respiratory diseases
03/28/2002WO2001074859A3 A gene differentially expressed in breast and bladder cancer and encoded polypeptides
03/28/2002WO2001072279A3 Medical emulsion for lubrication and delivery of drugs
03/28/2002WO2001066107A3 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases
03/28/2002WO2001064736A3 Proliferation arrest transcription factor and its use
03/28/2002WO2001064217A3 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
03/28/2002WO2001062793A3 Estrogen receptor beta variants and methods of detection thereof
03/28/2002WO2001057194A3 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
03/28/2002WO2001055357A3 Myeloid colony stimulating factor and uses thereof
03/28/2002WO2001055356A3 Human protein kinases and protein kinase-like enzymes
03/28/2002WO2001051642A3 Dna modification proteins
03/28/2002WO2001044177A3 Somatostatin analogs, radiolabelled derivatives thereof and their use
03/28/2002WO2001038552A3 Excipient system that contains coating substances with enzymatically removable side-groups
03/28/2002WO2001038486A3 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
03/28/2002WO2001035936A3 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases
03/28/2002WO2001032885A3 Human lipase
03/28/2002WO2001032216A3 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
03/28/2002WO2001022954A3 Indolyl-3-glyoxylic acid derivatives serving as antitumor agents
03/28/2002WO2001019353A3 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
03/28/2002WO2001009183A3 Polymorphisms in the human mdr-1 gene and applications thereof
03/28/2002WO2001007405A3 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments
03/28/2002WO2000063241A9 Methods and compositions for modulating an immune response
03/28/2002WO2000060051A3 Arpe-19 as a platform cell line for encapsulated cell-based delivery
03/28/2002WO2000048621A9 Methods and compositions for regulating protein-protein interactions
03/28/2002WO2000047722A3 Chimeric virus-like particles or chimeric capsomers from bvp (bovine papilloma virus)
03/28/2002WO2000047231A9 Novel antisense inhibition of rad51
03/28/2002US20020038038 Methods for treating pathological conditions of abnormal cell proliferation
03/28/2002US20020038028 For therapy of neurological and psychological disorders are claimed.
03/28/2002US20020038025 For therapy and prophylaxis of hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, diabetes
03/28/2002US20020038017 Synthesis of glycoconjugates of the lewis y epitope and uses thereof
03/28/2002US20020037929 Method of treating angiogenesis-related disorders
03/28/2002US20020037927 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
03/28/2002US20020037919 Compositions and methods of paclitaxel for preventing psoriasis
03/28/2002US20020037918 1-(aryl)-4-methyl-11-(hetrocycle)undeca-4,6,10-trien-1-ol for example; anticancer treatment, inhibit tubulin polymerization, inhibit binding of colchicine to tubulin, antiproliferative agents
03/28/2002US20020037917 Treatment of cancer using lipoic acid in combination with ascorbic acid
03/28/2002US20020037916 Inhibitors of matrix metallaproteinases
03/28/2002US20020037911 Arylthiazolidinedione derivatives
03/28/2002US20020037904 Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones, derivatives thereof and their uses
03/28/2002US20020037901 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis
03/28/2002US20020037900 Hydroxamic acid derivatives
03/28/2002US20020037897 Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
03/28/2002US20020037889 Imidazolidin-2-one derivatives; inhibiting bone resorption, vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, arthritis, viral disease, cancer and metastatic tumor growth
03/28/2002US20020037878 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/28/2002US20020037873 Biologically active phosphotriester-type compounds
03/28/2002US20020037870 Method of inhibiting cancer cell growth using a vector expressing pRb2/p130
03/28/2002US20020037866 Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
03/28/2002US20020037856 Novel compounds possessing antibacterial, antifungal or antitumor activity
03/28/2002US20020037852 Anticarcinogenic agents
03/28/2002US20020037850 Genetic engineering; binding to antibodies
03/28/2002US20020037847 Nucleic acids encoding kringle 1-5 region fragments of plasminogen
03/28/2002US20020037841 Blood disorders; drug in aqueous solution
03/28/2002US20020037836 Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
03/28/2002US20020037835 Antitumor agents
03/28/2002US20020037583 Transforming cells with preferfential nucleotide sequences; obtain cells, transform, with vector, express vector, recover preferential proteins
03/28/2002US20020037576 Method of producing infectious reovirus
03/28/2002US20020037572 Novel mammalian secreted group III phospholipase A2